Form D · Pharmaceuticals
Manzo Pharmaceuticals, Inc
Toronto, A6 · CIK 0001637132
Offering snapshot reported Dec 10, 2015 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $1K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $5M (estimated)
- Finders' fees
- $5M (estimated)
- Form D file number
- 021-252734
The gross amount of Sales Commissions & Finder's Fees combined is 10% [$5,000,000.00] based on the entire offering of $50,000,00.00 being sold out.
Source: Form D, filed Dec 10, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arthur Douglas Smitherman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
222 415 Oakdale Road
Toronto, A6, M3N 1W7
Toronto, A6, M3N 1W7